Selecting Treatment for Patients With Tardive Dyskinesia Using Safety and Efficacy Evidence.

This report outlines strategies to reduce TD symptoms, including the use of the FDA-approved treatment options (valbenazine and deutetrabenazine).
PMID: 32991793 [PubMed - as supplied by publisher]

Source: Journal of Clinical Psychiatry - September 30, 2020 Category: Psychiatry Tags: J Clin Psychiatry Source Type: research